Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Sedlis

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
Circulation. Cardiovascular Quality and Outcomes|July 11, 2013
Frequency, predictors, and consequences of crossing over to revascularization within 12 months of randomization to optimal medical therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trialJohn A Spertus, David J Maron, David J Cohen, et al.
Journal of the American College of Cardiology|July 2, 2011
Impact of metabolic syndrome and diabetes on prognosis and outcomes with early percutaneous coronary intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trialDavid J Maron, William E Boden, John A Spertus, et al.
The American Journal of Cardiology|May 12, 2015
Validation of the appropriate use criteria for percutaneous coronary intervention in patients with stable coronary artery disease (from the COURAGE trial)Steven M Bradley, Paul S Chan, Pamela M Hartigan, et al.
Journal of the American College of Cardiology|September 26, 2009
Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trialKoon K Teo, Steven P Sedlis, William E Boden, et al.
The American Journal of Cardiology|July 7, 2009
Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial)William E Boden, Robert A O'Rourke, Koon K Teo, et al.
The American Journal of Cardiology|October 6, 2009
Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trialDavid J Maron, John A Spertus, G B John Mancini, et al.
Circulation. Cardiovascular Interventions|November 3, 2011
Angiographic disease progression and residual risk of cardiovascular events while on optimal medical therapy: observations from the COURAGE TrialG B John Mancini, Pamela M Hartigan, Eric R Bates, et al.
American Heart Journal|September 11, 2013
Prognostic importance of coronary anatomy and left ventricular ejection fraction despite optimal therapy: assessment of residual risk in the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation TrialG B John Mancini, Pamela M Hartigan, Eric R Bates, et al.
JACC. Cardiovascular Interventions|January 21, 2014
Predicting outcome in the COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation): coronary anatomy versus ischemiaG B John Mancini, Pamela M Hartigan, Leslee J Shaw, et al.
Circulation. Cardiovascular Quality and Outcomes|December 25, 2009
Quantitative results of baseline angiography and percutaneous coronary intervention in the COURAGE trialG B John Mancini, Eric R Bates, David J Maron, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Circulation. Cardiovascular Quality and Outcomes|July 11, 2013
Frequency, predictors, and consequences of crossing over to revascularization within 12 months of randomization to optimal medical therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trialJohn A Spertus, David J Maron, David J Cohen, et al.
Journal of the American College of Cardiology|July 2, 2011
Impact of metabolic syndrome and diabetes on prognosis and outcomes with early percutaneous coronary intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trialDavid J Maron, William E Boden, John A Spertus, et al.
The American Journal of Cardiology|May 12, 2015
Validation of the appropriate use criteria for percutaneous coronary intervention in patients with stable coronary artery disease (from the COURAGE trial)Steven M Bradley, Paul S Chan, Pamela M Hartigan, et al.
Journal of the American College of Cardiology|September 26, 2009
Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trialKoon K Teo, Steven P Sedlis, William E Boden, et al.
The American Journal of Cardiology|July 7, 2009
Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial)William E Boden, Robert A O'Rourke, Koon K Teo, et al.
The American Journal of Cardiology|October 6, 2009
Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trialDavid J Maron, John A Spertus, G B John Mancini, et al.
Circulation. Cardiovascular Interventions|November 3, 2011
Angiographic disease progression and residual risk of cardiovascular events while on optimal medical therapy: observations from the COURAGE TrialG B John Mancini, Pamela M Hartigan, Eric R Bates, et al.
American Heart Journal|September 11, 2013
Prognostic importance of coronary anatomy and left ventricular ejection fraction despite optimal therapy: assessment of residual risk in the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation TrialG B John Mancini, Pamela M Hartigan, Eric R Bates, et al.
JACC. Cardiovascular Interventions|January 21, 2014
Predicting outcome in the COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation): coronary anatomy versus ischemiaG B John Mancini, Pamela M Hartigan, Leslee J Shaw, et al.
Circulation. Cardiovascular Quality and Outcomes|December 25, 2009
Quantitative results of baseline angiography and percutaneous coronary intervention in the COURAGE trialG B John Mancini, Eric R Bates, David J Maron, et al.
Pageof 7